Abstract:Myalgic encephalomyelitis (ME) or Chronic Fatigue Syndrome (CFS) is a neglected, debilitating multi-systemic disease without diagnostic marker or therapy. Despite evidence for neurological, immunological, infectious, muscular and endocrine pathophysiological abnormalities, the etiology and a clear pathophysiology remains unclear. The gut microbiome gained much attention in the last decade with manifold implications in health and disease. Here we review the current state of knowledge on the interplay between ME/CFS and the microbiome, to identify potential diagnostic or interventional approaches, and propose areas where further research is needed. We iteratively selected and elaborated on key theories about a correlation between microbiome state and ME/CFS pathology, developing further hypotheses. Based on the literature we hypothesize that antibiotic use throughout life favours an intestinal microbiota composition which might be a risk factor for ME/CFS. Main proposed pathomechanisms include gut dysbiosis, altered gut-brain axis activity, increased gut permeability with concomitant bacterial translocation and reduced levels of short-chain-fatty acids, D-lactic acidosis, an abnormal tryptophan metabolism and low activity of the kynurenine pathway. We review options for microbiome manipulation in ME/CFS patients including probiotic and dietary interventions as well as fecal microbiota transplantations. Beyond increasing gut permeability and bacterial translocation, specific dysbiosis may modify fermentation products, affecting peripheral mitochondria. Considering the gut-brain axis we strongly suspect that the microbiome may contribute to neurocognitive impairments of ME/CFS patients. Further larger studies are needed, above all to clarify whether D-lactic acidosis and early-life antibiotic use may be part of ME/CFS etiology and what role changes in the tryptophan metabolism might play. An association between the gut microbiome and the disease ME/CFS is plausible. As causality remains unclear, we recommend longitudinal studies. Activity levels, bedridden hours and disease progression should be compared to antibiotic exposure, drug intakes and alterations in the composition of the microbiota. The therapeutic potential of fecal microbiota transfer and of targeted dietary interventions should be systematically evaluated.

Leaky Gut In Chronic Fatigue Syndrome: A Review

Normalization of Leaky Gut in Chronic Fatigue Syndrome (CFS) is Accompanied by a Clinical Improvement: Effects of Age, Duration of Illness and the Translocation of LPS from Gram-Negative Bacteria.

Normalization of the Increased Translocation of Endotoxin from Gram Negative Enterobacteria (leaky Gut) is Accompanied by a Remission of Chronic Fatigue Syndrome.

Increased Serum Iga And Igm Against Lps Of Enterobacteria In Chronic Fatigue Syndrome (Cfs): Indication For The Involvement Of Gram-Negative Enterobacteria In The Etiology Of Cfs And For The Presence Of An Increased Gut-Intestinal Permeability

Chronic Fatigue Syndrome is Accompanied by an Igm-Related Immune Response Directed Against Neopitopes Formed by Oxidative or Nitrosative Damage to Lipids and Proteins

Inflammatory and Oxidative and Nitrosative Stress Pathways Underpinning Chronic Fatigue, Somatization and Psychosomatic Symptoms

Not in the Mind but in the Cell: Increased Production of Cyclo-Oxygenase-2 and Inducible NO Synthase in Chronic Fatigue Syndrome.

Increased IgA responses to the LPS of commensal bacteria is associated with inflammation and activation of cell-mediated immunity in chronic fatigue syndrome.

Aberrations in the Cross-Talks among Redox, Nuclear Factor-κB and Wnt/Catenin Pathway Signaling Underpin Myalgic Encephalomyelitis Andchronic Fatigue Syndrome: A Review and New Hypothesis Based on Results of Network, Enrichment and Annotation Analyses

Attenuation of Autoimmune Responses to Oxidative Specific Epitopes, but Not Nitroso-Adducts, is Associated with a Better Clinical Outcome in Myalgic Encephalomyelitis/chronic Fatigue Syndrome.

Environmental, Neuro-immune, and Neuro-oxidative Stress Interactions in Chronic Fatigue Syndrome

Oxidative and Nitrosative Stress and Immune-Inflammatory Pathways in Patients with Myalgic Encephalomyelitis (me)/chronic Fatigue Syndrome (CFS).

Evidence for the existence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) with and without abdominal discomfort (irritable bowel) syndrome.

Suppressed immune and metabolic responses to intestinal damage-associated microbial translocation in myalgic encephalomyelitis/chronic fatigue syndrome

Increased Expression of Activation Antigens on CD8+ T Lymphocytes in Myalgic Encephalomyelitis/chronic Fatigue Syndrome: Inverse Associations with Lowered CD19+ Expression and CD4+/CD8+ Ratio, but No Associations with (auto)immune, Leaky Gut, Oxidative and Nitrosative Stress Biomarkers.

Evidence for Inflammation and Activation of Cell-Mediated Immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Increased Interleukin-1, Tumor Necrosis Factor-Α, PMN-elastase, Lysozyme and Neopterin.

The Gut Microbiome in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS)

Aberrations in the Cross-Talks Among Redox, Nuclear Factor-κB, and Wnt/β-Catenin Pathway Signaling Underpin Myalgic Encephalomyelitis and Chronic Fatigue Syndrome

Mitochondrial dysfunctions in Myalgic Encephalomyelitis / chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways

Aberrations in the Cross-Talks Among Redox, Nuclear Factor-kappa B, and Wnt/beta-Catenin Pathway Signaling Underpin Myalgic Encephalomyelitis and Chronic Fatigue Syndrome

The gastrointestinal microbiota in the development of ME/CFS: a critical view and potential perspectives